Skip to main content

Twist Bioscience shares slide 20% after short seller compares synthetic DNA provider to Theranos, calling it a ‘cash-burning inferno’

Twist Bioscience Corp. stock slid 20% Tuesday, after a damning short seller report compared the company to the failed blood-testing startup Theranos, calling it a "cash-burning inferno" and a "'synthetic biology' swindle."
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.